Eli Lilly reports revenue growth driven by its obesity drug franchise
Forbes ties the quarter's expansion primarily to demand for the company's incretin-based weight loss and diabetes products.
The wire
- 01Forbes reports Eli Lilly posted large revenue growth attributed to its obesity drug portfolio.
- 02Sustained incretin demand shapes supply, pricing and contracting conditions that pharmacies and telehealth operators face.
- 03The report does not detail how much of the growth reflects volume versus price, or how it holds against competitors.
From the source
Read at forbes.comEli Lilly’s Obesity Drugs Drive Massive Revenue Growth